MentionFox
Home › Executive changes › Angiodynamics Inc
Leadership changes · ANGO · SEC Form 8-K, Item 5.02

Leadership changes at Angiodynamics Inc (2026)

Angiodynamics Inc (ANGO) leadership changes: 1 appointment and 1 departure reported on 2026-10-08. Who came in, who left and in what role, each cited to the company's own filing.

Sell to companies like these? Paste your website and see 10 with a filed reason to buy this month. Free.

Opens in a new tab. No signup.

Changes2
In (appointed)1
Out (departing)1
Latest filing2026-10-08

Angiodynamics Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-08. It names 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Angiodynamics Inc files it.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-10-08InEric HonrothPresident and Chief Executive Officer2026-11-028-K, 2026-10-08
2026-10-08OutHoward W. DonnellyDirector8-K, 2026-10-08

Selling to them or working with them? See who runs Angiodynamics Inc now and the warning signs.

Watch Angiodynamics Inc

Free to see. No signup.

Want the whole picture on Angiodynamics Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Angiodynamics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Angiodynamics Inc covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on Target: the verdict, 16 sections, 39 cited sources, dated 2026-09-28A real finished report, first screen. Opens in a new tab.

Leadership as last reported

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Angiodynamics Inc?

New leaders reset buying decisions — get the Full Report on Angiodynamics Inc: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Angiodynamics Inc

Hiring for a seat like this?

Find people with the same kind of experience as the President and Chief Executive Officer at Angiodynamics Inc, with the record behind each one.

Find candidates like President and Chief Executive Officer at Angiodynamics Inc

Every change, in the filing's words

Filed 2026-10-08 · 8-K

Appointed: Eric Honroth, President and Chief Executive Officer, effective 2026-11-02

On October 2, 2026, the Board of Directors of the Company (the " Board ") appointed Eric Honroth to serve as President and Chief Executive Officer of the Company, effective as of November 2, 2026 (the " Effective Date ") and concurrently with Mr. Clemmer's retirement.

Departing: Howard W. Donnelly, Director

Director Retirement On October 2, 2026, Howard W. Donnelly notified the Board of his intention to retire as a Class II director at the end of his current term.

Tools for this story

Each opens in a new tab, filled in for Angiodynamics Inc. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/angiodynamics
Last updated 2026-10-18
Primary record: SEC filing
Leadership changes at Angiodynamics Inc (2026). MentionFox, 2026-10-18. https://mentionfox.com/executive-changes/angiodynamics